Aptevo Historical Financial Ratios

APVO Stock  USD 4.09  5.92  59.14%   
Aptevo Therapeutics is presently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 6.37 or Days Sales Outstanding of 277 will help investors to properly organize and evaluate Aptevo Therapeutics financial condition quickly.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.

About Aptevo Financial Ratios Analysis

Aptevo TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Aptevo Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Aptevo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Aptevo Therapeutics history.

Aptevo Therapeutics Financial Ratios Chart

At this time, Aptevo Therapeutics' Income Quality is very stable compared to the past year. As of the 13th of December 2024, Net Debt To EBITDA is likely to grow to 0.43, while Price To Sales Ratio is likely to drop 154.18.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On EquityOperating Cycle
Cash Conversion Cycle

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Aptevo Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Aptevo Therapeutics sales, a figure that is much harder to manipulate than other Aptevo Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.
Most ratios from Aptevo Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Aptevo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.At this time, Aptevo Therapeutics' Income Quality is very stable compared to the past year. As of the 13th of December 2024, Net Debt To EBITDA is likely to grow to 0.43, while Price To Sales Ratio is likely to drop 154.18.
 2021 2022 2023 2024 (projected)
Days Sales Outstanding108.8293.03263.73276.91
PTB Ratio1.1K24.456.76.37

Aptevo Therapeutics fundamentals Correlations

-0.16-0.170.660.37-0.60.92-0.16-0.12-0.590.3-0.41-0.360.15-0.111.0-0.33-0.490.0-0.49-0.270.240.2-0.56-0.3-0.35
-0.16-0.11-0.320.210.33-0.021.00.120.330.110.530.22-0.40.84-0.16-0.03-0.07-0.16-0.07-0.280.14-0.96-0.05-0.130.11
-0.17-0.11-0.61-0.670.73-0.51-0.110.20.74-0.62-0.450.70.67-0.29-0.18-0.570.40.880.390.720.080.160.4-0.180.53
0.66-0.32-0.610.62-0.920.79-0.32-0.2-0.920.49-0.33-0.59-0.03-0.20.660.04-0.69-0.41-0.68-0.48-0.040.36-0.72-0.02-0.51
0.370.21-0.670.62-0.670.550.210.17-0.670.380.23-0.43-0.610.460.370.21-0.77-0.48-0.76-0.94-0.04-0.07-0.77-0.14-0.17
-0.60.330.73-0.92-0.67-0.750.330.241.0-0.550.080.710.260.12-0.6-0.110.590.450.580.64-0.07-0.330.620.060.58
0.92-0.02-0.510.790.55-0.75-0.02-0.25-0.750.43-0.22-0.58-0.060.040.93-0.13-0.55-0.36-0.55-0.480.20.04-0.61-0.23-0.5
-0.161.0-0.11-0.320.210.33-0.020.120.330.110.530.22-0.40.84-0.16-0.03-0.07-0.16-0.07-0.280.14-0.96-0.05-0.130.11
-0.120.120.2-0.20.170.24-0.250.120.250.150.110.29-0.180.21-0.140.04-0.490.28-0.5-0.10.090.1-0.45-0.280.21
-0.590.330.74-0.92-0.671.0-0.750.330.25-0.550.080.720.270.12-0.6-0.130.590.470.580.64-0.06-0.330.620.050.58
0.30.11-0.620.490.38-0.550.430.110.15-0.550.25-0.41-0.480.330.30.15-0.56-0.32-0.55-0.510.32-0.16-0.56-0.09-0.75
-0.410.53-0.45-0.330.230.08-0.220.530.110.080.250.06-0.860.56-0.410.620.16-0.360.16-0.41-0.18-0.560.190.320.12
-0.360.220.7-0.59-0.430.71-0.580.220.290.72-0.410.060.23-0.09-0.36-0.070.330.70.320.51-0.42-0.130.350.350.78
0.15-0.40.67-0.03-0.610.26-0.06-0.4-0.180.27-0.48-0.860.23-0.660.14-0.590.220.50.220.780.080.380.2-0.150.11
-0.110.84-0.29-0.20.460.120.040.840.210.120.330.56-0.09-0.66-0.110.02-0.25-0.29-0.25-0.610.33-0.81-0.22-0.3-0.15
1.0-0.16-0.180.660.37-0.60.93-0.16-0.14-0.60.3-0.41-0.360.14-0.11-0.32-0.49-0.01-0.49-0.280.240.19-0.56-0.29-0.35
-0.33-0.03-0.570.040.21-0.11-0.13-0.030.04-0.130.150.62-0.07-0.590.02-0.320.09-0.610.1-0.21-0.680.010.110.740.16
-0.49-0.070.4-0.69-0.770.59-0.55-0.07-0.490.59-0.560.160.330.22-0.25-0.490.090.181.00.63-0.19-0.121.00.380.34
0.0-0.160.88-0.41-0.480.45-0.36-0.160.280.47-0.32-0.360.70.5-0.29-0.01-0.610.180.170.50.140.230.18-0.220.42
-0.49-0.070.39-0.68-0.760.58-0.55-0.07-0.50.58-0.550.160.320.22-0.25-0.490.11.00.170.63-0.2-0.121.00.390.33
-0.27-0.280.72-0.48-0.940.64-0.48-0.28-0.10.64-0.51-0.410.510.78-0.61-0.28-0.210.630.50.63-0.130.20.630.20.32
0.240.140.08-0.04-0.04-0.070.20.140.09-0.060.32-0.18-0.420.080.330.24-0.68-0.190.14-0.2-0.13-0.19-0.2-0.9-0.64
0.2-0.960.160.36-0.07-0.330.04-0.960.1-0.33-0.16-0.56-0.130.38-0.810.190.01-0.120.23-0.120.2-0.19-0.130.060.03
-0.56-0.050.4-0.72-0.770.62-0.61-0.05-0.450.62-0.560.190.350.2-0.22-0.560.111.00.181.00.63-0.2-0.130.380.36
-0.3-0.13-0.18-0.02-0.140.06-0.23-0.13-0.280.05-0.090.320.35-0.15-0.3-0.290.740.38-0.220.390.2-0.90.060.380.39
-0.350.110.53-0.51-0.170.58-0.50.110.210.58-0.750.120.780.11-0.15-0.350.160.340.420.330.32-0.640.030.360.39
Click cells to compare fundamentals

Aptevo Therapeutics Account Relationship Matchups

Aptevo Therapeutics fundamentals Accounts

201920202021202220232024 (projected)
Price To Sales Ratio30.51.1K111.05141.13162.3154.18
Ptb Ratio83.51277.11.1K24.456.76.37
Book Value Per Share178.62215.3211.41154.4743.9541.75
Free Cash Flow Yield(0.0496)(0.043)(0.006395)(0.0164)(0.0479)(0.14)
Operating Cash Flow Per Share(639.3)(380.43)(203.47)(180.67)(42.19)(44.29)
Stock Based Compensation To Revenue0.04930.290.130.580.670.8
Capex To Depreciation0.06850.06260.620.03220.0370.0352
Pb Ratio83.51277.11.1K24.456.76.37
Ev To Sales30.831.1K108.75136.92123.23175.54
Free Cash Flow Per Share(641.61)(381.57)(210.17)(180.92)(42.19)(44.29)
Roic(1.21)(0.39)(1.2)(8.13)(2.36)(2.48)
Inventory Turnover3.253.736.160.570.520.49
Net Income Per Share(610.11)(239.38)(256.35)366.71(62.62)(65.75)
Days Of Inventory On Hand112.4597.7959.23636.42731.88768.48
Payables Turnover0.963.13.25.490.260.14
Research And Ddevelopement To Revenue0.764.141.555.746.66.27
Capex To Revenue0.0047190.02040.0580.0093130.01070.0102
Cash Per Share187.76518.76422.77194.5360.7957.75
Pocfratio(23.33)(156.84)(62.97)(20.91)(6.99)(7.33)
Capex To Operating Cash Flow(0.00361)(0.003002)(0.0329)(0.00138)(0.001242)(0.001304)
Pfcf Ratio(23.25)(156.37)(60.96)(20.88)(6.99)(7.33)
Days Payables Outstanding117.74114.1566.531.4K2.6K2.7K
Income Quality1.051.650.76(2.62)0.670.71
Roe(3.42)(1.11)(22.46)2.37(1.42)(1.5)
Ev To Operating Cash Flow(23.59)(156.41)(61.66)(20.28)(6.0)(6.3)
Pe Ratio(24.45)(249.25)(49.98)10.3(4.71)(4.94)
Return On Tangible Assets(0.83)(0.34)(0.48)1.25(0.7)(0.74)
Ev To Free Cash Flow(23.5)(155.94)(59.7)(20.25)(6.0)(6.3)
Earnings Yield(0.0409)(0.004012)(0.02)0.0971(0.21)(0.2)
Net Debt To E B I T D A(0.27)0.481.40.470.410.43
Current Ratio0.783.251.513.152.642.95
Tangible Book Value Per Share111.95215.3211.41154.4743.9541.75
Graham Number1.6K1.1K256.571.1K248.84236.4
Shareholders Equity Per Share178.62215.3211.41154.4743.9541.75
Debt To Equity1.681.5112.640.190.170.16
Capex Per Share2.311.146.690.250.290.27

Pair Trading with Aptevo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Aptevo Stock

  0.54IMAB I MabPairCorr
  0.43GNFT GenfitPairCorr
  0.38FLGC Flora Growth CorpPairCorr
  0.38LLY Eli LillyPairCorr
  0.36PFE Pfizer Inc Fiscal Year End 4th of February 2025 PairCorr
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(415.99)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.73)
Return On Equity
(2.51)
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.